Reduced serum hydroxyl radical scavenging activity in erythropoietin therapy resistant renal anemia

Free Radical Research

Volumn 36, Issue 11, 2002, Pages 1155-1161

  Hirayama, Aki ^a   Nagase, Sohji ^a   Gotoh, Michihiro ^b   Ueda, Atsushi ^a   Ishizu, Takashi ^c   Yoh, Keigyou ^a   Aoyagi, Kazumasa ^d   Terao, Junji ^e   Koyama, Akio ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b Hitachi   (Japan)

^c Tsukuba Central Hospital   (Japan)

^d TSUKUBA UNIVERSITY OF TECHNOLOGY   (Japan)

^e UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Erythropoietin; Hemodialysis; Hydroxyl radical; Lipid peroxidation; Renal anemia

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; FERRITIN; HEMOGLOBIN; HYDROXYL RADICAL; ICOSAPENTAENOIC ACID; IRON DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; SUPEROXIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; AGED; ANEMIA; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ELECTRON SPIN RESONANCE; ERYTHROCYTE LEVEL; FEMALE; FERRITIN BLOOD LEVEL; HEMATOPOIESIS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY FAILURE; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; SCAVENGING SYSTEM; SIGNAL TRANSDUCTION;

AGED; ANEMIA; DRUG RESISTANCE; ELECTRON SPIN RESONANCE SPECTROSCOPY; ERYTHROCYTE MEMBRANE; ERYTHROCYTES; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FERRITINS; FREE RADICAL SCAVENGERS; HUMANS; HYDROXYL RADICAL; KIDNEY FAILURE, CHRONIC; LIPID PEROXIDATION; MALE; MIDDLE AGED; RENAL DIALYSIS; SUPEROXIDES; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 0036828210     PISSN: 10715762     EISSN: None     Source Type: Journal    
DOI: 10.1080/1071576021000016418     Document Type: Article

References (18)

1. National Kidney Foundation-Dialysis Outcomes Quality Initiative (1997) "NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure", Am. J. Kidney Dis., S192-S240.
2. Evans, R.W., Rader, B. and Manninen, D.L. (1990) "The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group", J. Am. Med. Assoc. 263, 825-830.
3. Nissenson, A.R. (1998) "Optimal hematocrit in patients on dialysis therapy", Am. J. Kidney Dis., S142-S146.
4. Macdougall, I.C. (1995) "Poor response to erythropoietin: practical guidelines on investigation and management", Nephrol. Dial. Transplant. 10, 607-614.
5. Nagase, S., Aoyagi, K., Hirayama, A., Gotoh, M., Ueda, A., Tomida, C., Kamezaki, T., Nagai, Y., Kikuchi, H. and Koyama, A. (1997) "Favorable effect of hemodialysis on decreased serum antioxidant activity in hemodialysis patients demonstrated by electron spin resonance", J. Am. Soc. Nephrol. 8, 1157-1163.
6. Hirayama, A., Nagase, S., Gotoh, M., Takemura, K., Tomida, C., Ueda, A., Aoyagi, K., Terao, J. and Koyama, A. (2000) "Hemodialysis does not influence the peroxidative state already present in uremia", Nephron 86, 436-440.
7. Boaz, M., Matas, Z., Biro, A., Katzir, Z., Green, M., Fainaru, M. and Smetana, S. (1999) "Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis", Kidney Int. 56, 1078-1083.
8. Boaz, M., Smetana, S., Weinstein, T., Matas, Z., Gafter, U., Laina, A., Knecht, A., Weissgarten, Y., Brunner, D., Fairnaru, M. and Green, M.S. (2000) "Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial", Lancet 356, 1213-1218.
9. Browne, P., Shalev, O. and Hebbel, R.P. (1998) "The molecular pathobiology of cell membrane iron: the sickle red cell as a model", Free Radic. Biol. Med. 24, 1040-1048.
10. Gotoh, M., Nagase, S., Aoyagi, K., Hirayama, A., Takemura, K., Ueda, A., Tomida, C., Kikuchi, H. and Koyama, A. (1997) "Thiobarbituric acid reactive substances are increased in the subcutaneous fat tissue of patients with end-stage renal disease", Nephrol. Dial. Transplant. 12, 713-717.
11. Noda, Y., Anzai, K., Mori, A., Kohno, M., Shinmei, M. and Packer, L. (1997) "Hydroxyl and superoxide anion radical scavenging activities of natural source antioxidants using the computerized JES-FR30 ESR spectrometer system", Biochem. Mol. Biol. Int. 42, 35-44.
12. Sommerburg, O., Grune, T., Hampl, H., Riedel, E., Van, K.F., Ehrich, J.H. and Siems, W.G. (1998) "Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients?", Nephrol. Dial. Transplant. 13, 2583-2587.
13. Gallucci, M.T., Lubrano, R., Meloni, C., Morosetti, M., Manca di Villahermosa, S., Scoppi, P., Palombo, G., Castello, M.A. and Casciani, C.U. (1999) "Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients", Clin. Nephrol. 52, 239-245.
14. Stohs, S.J. and Bagchi, D. (1995) "Oxidative mechanisms in the toxicity of metal irons", Free Radic. Biol. Med. 18, 321-336.
15. Repka, T. and Hebbel, R.P. (1991) "Hydroxyl radical formation by sickle erythrocyte membranes: role of pathologic iron deposits and cytoplasmic reducing agents", Blood 78, 2753-2758.
16. Besarab, A., Amin, N., Ahsan, M., Vogel, S.E., Zazuwa, G., Frinak, S., Zazra, J.J., Anandan, J.V. and Gupta, A. (2000) "Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients", J. Am. Soc. Nephrol. 11, 530-538.
17. Phumala, N., Ide, T. and Utsumi, H. (1999) "Noninvasive evaluation of in vivo free radical reactions catalyzed by iron using in vivo ESR spectroscopy", Free Radic. Biol. Med. 26, 1209-1217.
18. Patruta, S.I. and Horl, W.H. (1999) "Iron and infection", Kidney Int. Suppl., S125-S130.